The Thailand flu diagnostic and treatment market is projected to grow at a CAGR of 7.03% throughout the forecast period. The market was valued at US$97.639 million in 2020 and is anticipated to reach a value of US$157.109 million by 2027. The flu diagnostic and treatment market in Thailand is poised to surge at a significant rate during the coming years owing to the fact that easy availability of cheaper OTC medicines for cough, cold, and allergies along with the rapid increase in influenza cases throughout the country are collectively contributing to positively impacting the market growth in the country. However, the lack of effectiveness of such medications has called for the need for more advanced vaccinations and treatment efforts; thus, fueling the market in the coming years.
The growth in the number of cases is one of the prime factors that is projected to supplement the demand for flu diagnostic and treatment solutions in the country, which is thereby projected to boost the flu diagnostic and treatment market in Thailand during the coming years. For instance, according to the Bureau of Emerging Infectious Diseases, which comes under the Ministry of Public Health’s Department of Disease Control, in 2017, the total number of influenza cases was reported to be around 165,000, an increase of 50,000 cases was also observed by the end of 2017, which further shows the growing intensity of the influenza virus throughout the country which is anticipated to positively impact the market growth of flu diagnostics and treatment in the country during the forecast period and beyond. Furthermore, the rising number of flu cases is expected over the next few years which is also considered an important factor for the flu diagnostic and treatment market to surge during the forecast period and beyond. Furthermore, the availability of cheaper OTC medicines is also positively impacting market growth in Thailand. In addition, the advisory committee, namely, Immunization Practice in Thailand, also provides seasonal influenza vaccinations for high-risk population groups. The government’s exclusive purchase of vaccines for such people also shows the potential for the market to surge during the coming years.
The Thailand flu and diagnostics market has been segmented on the basis of the type of flu, offering, age group, and end-user. On the basis of the type of flu, the market has been classified into type A and type B. By offering, the market has been segmented into diagnostics and therapeutics. The market has been segmented on the basis of the age groups of 0-14 years, 15-64 years, and >=65 years. By the end-user, the segmentation has been done on the basis of a hospital laboratory, outpatient clinic, and reference laboratory.
Key Developments in the Market:
COVID-19 Insights:
COVID-19 had a positive impact on the Thailand Flu and diagnostic market. The growing prevalence of influenza and COVID-19 and the similarity between the symptoms of the two led to the increased usage of influenza diagnostic kits to accurately detect the source of the infection. Furthermore, the increasing government initiatives to prevent the spread of seasonal flu led to increased demand in the market amid the pandemic.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2020 | US$97.639 million |
| Market Size Value in 2027 | US$157.109 million |
| Growth Rate | CAGR of 7.03% from 2020 to 2027 |
| Base Year | 2020 |
| Forecast Period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Type of Flu, Offering, Age Group, And End-User |
| Companies Covered | Abbott, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., 3M, BD, SA Scientific |
| Customization Scope | Free report customization with purchase |
Key Market Segmentation